Friday, July 10, 2026
🇺🇸 FDA

pharma · Multiple Myeloma · Relapsed/Refractory Multiple Myeloma

Janssen-Cilag International N.V

Janssen-Cilag International N.V.

Janssen-Cilag International N.V trial registry — 161 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
São Paulo, EU HQ
13 Employees
EMA registrant Type
Company details
Status
Public
HQ
São Paulo, EU
Employees
13
Programs
161
Drugs
159
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Trials

Janssen-Cilag International N.V clinical trials

Registry index of 161 ClinicalTrials.gov studies linked to Janssen-Cilag International N.V programs — each row shows trial ID, program name, phase, status, and indication.

Janssen-Cilag International N.V trial registry — 161 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for Janssen-Cilag International N.V.

  1. 90014496LYM1001 — Phase 1

    Clinical update

  2. 87189401PCR1001 — Phase 1

    Clinical update

  3. 77242113PSO3003 — Phase 3

    Clinical update

  4. 77242113PSO3001 — Phase 3

    Clinical update

  5. 64407564MMY1004 — Phase 1

    Clinical update

  6. A study to compare the amount of milvexian in... — Phase 1

    Clinical update

  7. A Phase 1 Study of JNJ-79032421 Targeting Mes... for Advanced Stage Solid Tumors — Phase 1

    Clinical update

  8. 90301900HNC1001 — Phase 1

    Clinical update

Trial registry

161 studies
  99. 2023-509560-16-00

    CNTO1959ISD3001

    Phase 3 active small_molecule

    Juvenile psoriatic arthritis (jPsA), Moderately to severely active ulcerative colitis (UC), Moderately to severely active Crohn's disease (CD)

    CTIS ↗
  105. 2023-510306-40-00

    42756493BLC2003

    Phase 2 active small_molecule

    Cohort 1 and 2: High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions Cohort 3 Intermediate Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions

    CTIS ↗

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.